Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy

PROPOSE: Pregnancy is a risk factor for severe COVID-19. Treatment with monoclonal antibodies has been shown to decrease the risk of progression to severe COVID-19, but there are few reports on treating pregnant women. Here, we describe the clinical outcome of seven hospitalized pregnant women treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Folkman, Rebecca, Blennow, Ola, Tovatt, Tuulikki, Pettersson, Karin, Nowak, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046532/
https://www.ncbi.nlm.nih.gov/pubmed/35482208
http://dx.doi.org/10.1007/s15010-022-01829-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046532/
https://www.ncbi.nlm.nih.gov/pubmed/35482208
http://dx.doi.org/10.1007/s15010-022-01829-4

Ejemplares similares